Visa reported fiscal Q2 2026 net revenue of $11.230B, up 17% nominal and 16% on a constant-dollar basis — the highest growth rate the company has printed since 2022 and 200 basis points above the +15% Q1 FY2026 mark. Non-GAAP EPS reached $3.31 (+20% YoY); GAAP EPS hit $3.14 (+36% YoY) on a normalizing litigation provision. The board layered a fresh $20B multi-year buyback authorization on top of the $13.2B already remaining. The stock closed today at $309.30 versus $314.08 at the prior assessment — drifting modestly lower while the underlying business clearly accelerated. The DIVERGING narrative-reality gap that the February deep-dive flagged is widening, not closing.
The Numbers
What Changed: Two Signals With Stronger Evidence
No signal flips and no lens warrants a re-run. Two signals carry materially stronger evidence after Q2:
- Gravy Gauge — REVENUE_DURABILITY: Status remains CONDITIONAL, but the boundary distance to FRAGILE widened. Cross-border excluding intra-Europe held +11% for a second straight quarter, and the client incentive ratio moved further from 30% (now 27.43% vs 28.3% baseline). The structural-deceleration worry that anchored the bear case has weaker footing after two clean prints.
- Myth Meter — NARRATIVE_REALITY_GAP: DIVERGING with stronger evidence. Net revenue +17%, non-GAAP EPS +20%, and a $20B fresh buyback against a stock that drifted to $309.30 from $314.08 widens the gap rather than closing it. The MODEST EXPECTATIONS_PRICED classification rests on more data points today than at run-time.
Other revenue grew +41% and data processing revenue grew +18% — both materially above the +9% payments volume growth. That is indirect but consistent evidence that VAS momentum continued in Q2, even though the 8-K does not break out VAS as a discrete line item. The Q1 transcript pegged VAS at +28% constant-dollar with a 50% revenue growth attribution; the Q2 dynamics look broadly consistent.
Forecast Markets: Zero Resolved, Three Priors Materially Shift
All nine active V markets remain open. Five resolve on FY2026 close (December 2026), one (cross-border) on Q3 close (August 2026), and three in 2027 (DOJ trial, FedNow, P/E compression, CCCA). Q2 supplied material data points on three of them:
| Market | Prior | Direction | Driver |
|---|---|---|---|
| FY26 net revenue growth >= 12% | 0.43 | higher | H1 ran at +15.8% nominal; H2 would need to print under ~8% constant to miss |
| Q2 or Q3 cross-border < 10% | 0.59 | lower | Q2 locked at +11% (above 10%); resolves only on Q3 alone now |
| FY26 client incentive ratio > 30% | 0.10 | lower | Q2 came in at 27.43%, compressed from 28.3% baseline |
| VAS growth > 20% all remaining quarters | 0.63 | higher | Other revenue +41%, data processing +18% — indirect support |
| CCCA committee/floor vote by Dec 2026 | 0.36 | unchanged | External to earnings; no Q2 update |
| DOJ trial date or settlement by Jun 2027 | 0.43 | unchanged | $329M Q2 provision is interchange MDL, not DOJ debit case |
Litigation provisioning normalized to $329M in Q2 versus $1.0B in the prior-year quarter, with $311M attributable to the interchange MDL rather than the DOJ debit case. That is consistent with the prior view that the FY2025 $2.6B special charge largely true-upped near-term legal exposure rather than starting an escalating cadence. It does not update the DOJ trial date market, which is driven by court timeline rather than provisioning.
What's Still Active
- Class B exchange offer (expires May 8, 2026): Visa commenced an exchange offer on April 13 to swap outstanding Class B-1 and B-2 shares for a combination of new Class B-3, Class C, and cash for fractional shares. Structural simplification, not a change of control. Watch participation rate at expiration.
- Argentine antitrust review of Prisma + Newpay: Acquisition closed February 2026 (~$705M cash use); Argentine competition authority review is the open conditional. Strengthens Latin America issuer-processing footprint.
- $20B new buyback velocity: Q2 alone consumed $7.9B of the prior authorization at an average price of $320.66 — above today's $309.30 close. Combined ~$33B capacity at current pace would exhaust within four quarters.
- CCCA legislative calendar (H2 2026): The 36% probability remains the dominant escalation signal. NDAA and appropriations vehicles are the relevant test windows.
The Bigger Picture
The thesis stays price-below-value with MEDIUM confidence. Q2 strengthens the operational pillar; the regulatory pillar is unchanged. The minor upward-pressure magnitude reflects that the apparent undervaluation is not large — Visa is trading at a modest discount to intrinsic value, not a deep one — and the compound CCCA/DOJ tail (10-17% per the Black Swan Beacon) could still produce 15-22% revenue impact and 30-50% equity impairment if it materializes. That risk has not been bought down by today's release.
VAS margin economics remain undisclosed in the Q2 8-K — the most-cited adaptation hedge across all eight lenses still has unverified profitability. Whether the +41% Other revenue growth is margin-accretive or margin-dilutive is the single largest analytical gap from run-time, and Q2 did not close it. On balance the asymmetry has widened in the buyer's direction; the regulatory risk profile is unchanged.
See the full eight-lens V analysis
The February 2026 V deep-dive with the Regulatory Reader, Moat Mapper, Gravy Gauge, Myth Meter, Stress Scanner, Consolidation Calibrator, Insider Investigator, and Black Swan Beacon outputs, plus the nine forecast markets tracking the thesis.
Public Sources Used
- Visa Inc. Q2 FY2026 Form 8-K (SEC EDGAR, filed 2026-04-28; Item 2.02 plus Exhibit 99.1 press release; Item 8.01 dividend and buyback authorization): SEC EDGAR
- Visa Q1 FY2026 earnings call transcript (Jan 29, 2026; CEO Ryan McInerney, CFO Chris Suh) — baseline reference for VAS constant-dollar disclosure
- Visa FY2025 10-K (baseline analysis reference)
- Visa S-4/A and Class B exchange offer materials (commenced April 13, 2026; expires May 8, 2026)
- Visa thesis assessment (2026-04-28); nine-market ensemble outputs